Important pharmacogenetic information for drugs prescribed during the SARS-CoV-2 infection (COVID-19)
Entidad
UAM. Departamento de FarmacologíaEditor
Wiley; Society for Clinical and Translational ScienceFecha de edición
2020-09-16Cita
10.1111/cts.12866
Clinical and Translational Science (2020): 16 September
ISSN
1752-8054 (print); 1752-8062 (online)DOI
10.1111/cts.12866Financiado por
M.N.-G. is co-financed by the European Social Fund and the Youth European Initiative; grant number PEJ-2018-TL/BMD-11080Versión del editor
https://doi.org/10.1111/cts.12866Materias
SARS‐CoV‐2; COVID-19; drugs; pharmacogenetic biomarkers; MedicinaDerechos
© 2020 The AuthorsResumen
In December 2019, the severe acute respiratory syndrome virus-2 pandemic began, causing the coronavirus disease 2019. A vast variety of drugs is being used off-label as potential therapies. Many of the repurposed drugs have clinical pharmacogenetic guidelines available with therapeutic recommendations when prescribed as indicated on the drug label. The aim of this review is to provide a comprehensive summary of pharmacogenetic biomarkers available for these drugs, which may help to prescribe them more safely
Lista de ficheros
Google Scholar:Zubiaur, Pablo
-
Koller, Dora
-
Saiz-Rodríguez, Miriam
-
Navares-Gómez, Marcos
-
Abad Santos, Francisco
Lista de colecciones del ítem
Registros relacionados
Mostrando ítems relacionados por título, autor, creador y materia.